Predictive Low-Glucose Suspend Reduces Hypoglycemia in Adults, Adolescents, and Children With Type 1 Diabetes in an At-Home Randomized Crossover Study: Results of the PROLOG Trial
The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: This study evaluated a new insulin delivery system designed to reduce insulin delivery when trends in continuous glucose monitoring (CGM) glucose concentrations predict future hypoglycemia. RESEARCH DESIGN AND METHODS: Individuals with type 1 diabetes (n = 103, age 6–72 years, mean HbA1c 7.3% [56 mmol/mol]) participated in a 6-week randomized crossover trial to evaluate the efficacy and safety of a Tandem Diabetes Care t:slim X2 pump with Basal-IQ integrated with a Dexcom G5 sensor and a predictive low-glucose suspend algorithm (PLGS) compared with sensor-augmented pump (SAP) therapy. The primary outcome was CGM-measured time <70 mg/dL. RESULTS: Both study periods were completed by 99% of participants; median CGM usage exceeded 90% in both arms. Median time <70 mg/dL was reduced from 3.6% at baseline to 2.6% during the 3-week period in the PLGS arm compared with 3.2% in the SAP arm (difference [PLGS − SAP] = −0.8%, 95% CI −1.1 to −0.5, P < 0.001). The corresponding mean values were 4.4%, 3.1%, and 4.5%, respectively, represent-ing a 31% reduction in the time <70 mg/dL with PLGS. There was no increase in mean glucose concentration (159 vs. 159 mg/dL, P = 0.40) or percentage of time spent >180 mg/dL (32% vs. 33%, P = 0.12). One severe hypoglycemic event occurred in the SAP arm and none in the PLGS arm. Mean pump suspension time was 104 min/day. CONCLUSIONS: The Tandem Diabetes Care Basal-IQ PLGS system significantly reduced hypoglycemia without rebound hyperglycemia, indicating that the system can benefit adults and youth with type 1 diabetes in improving glycemic control.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Partial closed-loop therapy, such as predictive low-glucose suspend (PLGS) technology, has been shown in nonpregnant people to be better than sensoraugmented insulin pumps (SAP) for reducing low glucose values (108).”
From 15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes—2024 (2024) · cites this paper as [108]
In the citing paper
“Both generation 1 low-glucose-suspend33 and generation 2 hybrid closed-loop systems improve glycated haemoglobin concentrations, the time in target range and the time below target range in children, adolescents34 and adults.35-37”
From Blood glucose monitoring devices: current considerations (2023) · cites this paper as [33]
In the citing paper
“Reduction of nocturnal hypoglycemia in individuals with type 1 diabetes using insulin pumps with CGM is improved by automatic suspension of insulin delivery at a preset glucose level, with further improvements when using devices with predictive low-glucose insulin delivery suspension (24,25).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [25]
In the citing paper
“Predictive lowglucose suspend systems have been shown to reduce time spent with glucose <70 mg/dL without rebound hyperglycemia during a 6-week randomized crossover trial (190).”
From 7. Diabetes Technology: Standards of Care in Diabetes—2025 (2025) · cites this paper as [190]
Citations
Cites
Adaptive linear step-up procedures that control the false discovery rate
Benjamini, Y., Krieger, A. M., & Yekutieli, D. (2006) · Biometrika · doi:10.1093/biomet/93.3.491 · Cited by 3,228 · cited 1×
“All nominal (uncorrected) P values except those from the primary and safety analyses were adjusted for multiple comparisons using the Benjamini-Hochberg adaptive false discovery procedure (24).”
MethodInternational consensus on use of continuous glucose monitoring
Danne, T., Nimri, R., Battelino, T., Bergenstal, R. M., Close, K. L., DeVries, J. H., Garg, S., Heinemann, L., Hirsch, I., Amiel, S. A., et al. (2017) · Diabetes Care · doi:10.2337/dc17-1600 · Cited by 2,069 · cited 1×
“Percentage of time,54 mg/dL was added as a post hoc outcome to conform with a recent consensus classification of hypoglycemia (21).”
MethodSelf-citationSeaquist, E. R., Anderson, J., Childs, B., Cryer, P., Dagogo-Jack, S., Fish, L., Heller, S. R., Rodriguez, H., Rosenzweig, J., & Vigersky, R. (2013) · Diabetes Care · doi:10.2337/dc12-2480 · Cited by 1,389
Estimates of Location Based on Rank Tests
Hodges, J. L., & Lehmann, E. L. (1963) · The Annals of Mathematical Statistics · doi:10.1214/aoms/1177704172 · Cited by 1,260 · cited 1×
“parametric analysis based on ranks was performed (23).”
MethodMiller, K. M., Foster, N. C., Beck, R. W., Bergenstal, R. M., DuBose, S. N., DiMeglio, L. A., Maahs, D. M., & Tamborlane, W. V. (2015) · Diabetes Care · doi:10.2337/dc15-0078 · Cited by 1,254 · cited 5×
“ticipants using an insulin pump and CGM before the study were higher and baseline HbA1c levels were lower than the national averages for adults and children with type 1 diabetes (9).”
BackgroundInfluentialSelf-citationThreshold-based insulin-pump interruption for reduction of hypoglycemia
Bergenstal, R. M., Klonoff, D. C., Garg, S. K., Bode, B. W., Meredith, M., Slover, R. H., Ahmann, A. J., Welsh, J. B., Lee, S. W., & Kaufman, F. R. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303576 · Cited by 652 · cited 1×
“8% fewer nocturnal hypoglycemia events using a threshold suspend system compared with sensor-augmented pump (SAP) therapy (10).”
MethodSafety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes
Bergenstal, R. M., Garg, S., Weinzimer, S. A., Buckingham, B. A., Bode, B. W., Tamborlane, W. V., & Kaufman, F. R. (2016) · JAMA · doi:10.1001/jama.2016.11708 · Cited by 644
Self-citationGarg, S. K., Weinzimer, S. A., Tamborlane, W. V., Buckingham, B. A., Bode, B. W., Bailey, T. S., Brazg, R. L., Ilany, J., Slover, R. H., Anderson, S. M., et al. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0421 · Cited by 585
Self-citationWeisman, A., Bai, J.-W., Cardinez, M., Kramer, C. K., & Perkins, B. A. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30167-5 · Cited by 463
Determining what individual SUS scores mean
(2009) · Journal of Usability Studies archive · doi:10.5555/2835587.2835589 · Cited by 412
Weinstock, R. S., Xing, D., Maahs, D. M., Michels, A., Rickels, M. R., Peters, A. L., Bergenstal, R. M., Harris, B., DuBose, S. N., Miller, K. M., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1589 · Cited by 338 · cited 2×
“8 1 (,1) 2 (2) 12 (12) 34 (33) 53 (52)”
BackgroundSelf-citationHypoglycemia in Type 1 Diabetes Mellitus
Cryer, P. E. (2010) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2010.05.003 · Cited by 205
Kovatchev, B. P., Clarke, W. L., Breton, M., Brayman, K., & McCall, A. (2005) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2005.7.849 · Cited by 201 · cited 1×
“Secondary hypoglycemia outcomes included percentage of glucose values ,60 mg/dL, ,50 mg/dL, area over the curve (70 mg/dL), low blood glucose index (20), and frequency of CGM-measured hypoglycemic events (defined as at least two sensor values ,54 mg/dL that were $15 min apart plus no intervening values $54 mg/dL, with…”
BackgroundBreton, M. D., Cherñavvsky, D. R., Forlenza, G. P., DeBoer, M. D., Robic, J., Wadwa, R. P., Messer, L. H., Kovatchev, B. P., & Maahs, D. M. (2017) · Diabetes Care · doi:10.2337/dc17-0883 · Cited by 179
Self-citationA Randomized Trial of a Home System to Reduce Nocturnal Hypoglycemia in Type 1 Diabetes
Maahs, D. M., Calhoun, P., Buckingham, B. A., Chase, H. P., Hramiak, I., Lum, J., Cameron, F., Bequette, B. W., Aye, T., Paul, T., et al. (2014) · Diabetes Care · doi:10.2337/dc13-2159 · Cited by 160
Self-citationBattelino, T., Nimri, R., Dovč, K., Phillip, M., & Bratina, N. (2017) · Diabetes Care · doi:10.2337/dc16-2584 · Cited by 157
Frequency and Timing of Severe Hypoglycemia Affects Spatial Memory in Children With Type 1 Diabetes
Hershey, T., Perantie, D. C., Warren, S. L., Zimmerman, E. C., Sadler, M., & White, N. H. (2005) · Diabetes Care · doi:10.2337/diacare.28.10.2372 · Cited by 156 · cited 1×
“This is particularly concerning in children, in whom recurrent hypoglycemia has been associated with declines in cognitive performance and memory (7,8).”
BackgroundAbraham, M. B., Nicholas, J. A., Smith, G. J., Fairchild, J. M., King, B. R., Ambler, G. R., Cameron, F. J., Davis, E. A., Jones, T. W., & on behalf of the PLGM Study Group (2018) · Diabetes Care · doi:10.2337/dc17-1604 · Cited by 142
Buckingham, B. A., Raghinaru, D., Cameron, F., Bequette, B. W., Chase, H. P., Maahs, D. M., Slover, R., Wadwa, R. P., Wilson, D. M., Ly, T., et al. (2015) · Diabetes Care · doi:10.2337/dc14-3053 · Cited by 139
Self-citationBiester, T., Kordonouri, O., Holder, M., Remus, K., Kieninger-Baum, D., Wadien, T., & Danne, T. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0349 · Cited by 128 · cited 1×
“(25) also have published outpatient results for the MiniMed 640G compared against SAP in a crossover trial in which they showed that use of the PLGS system was associated with a reduction in time ,70 mg/dL from 73 to 31 min/day.”
MethodMesser, L. H., Forlenza, G. P., Sherr, J. L., Wadwa, R. P., Buckingham, B. A., Weinzimer, S. A., Maahs, D. M., & Slover, R. H. (2018) · Diabetes Care · doi:10.2337/dc17-1682 · Cited by 126
Self-citationBlasetti, A., Chiuri, R. M., Tocco, A. M., Giulio, C. D., Mattei, P. A., Ballone, E., Chiarelli, F., & Verrotti, A. (2011) · Journal of Child Neurology · doi:10.1177/0883073811406730 · Cited by 118 · cited 1×
“This is particularly concerning in children, in whom recurrent hypoglycemia has been associated with declines in cognitive performance and memory (7,8).”
BackgroundChoudhary, P., Olsen, B. S., Conget, I., Welsh, J. B., Vorrink, L., & Shin, J. J. (2016) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2015.0324 · Cited by 118 · cited 1×
“Relatively shorter suspensions were seen in the current study, with a mean suspension duration of 18 min per event, whereas suspensions for other trials were 56 and 58min (16,17).”
BackgroundBuckingham, B. A., Cameron, F., Calhoun, P., Maahs, D. M., Wilson, D. M., Chase, H. P., Bequette, B. W., Lum, J., Sibayan, J., Beck, R. W., et al. (2013) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2013.0040 · Cited by 102
Self-citationLy, T. T., Gallego, P. H., Davis, E. A., & Jones, T. W. (2009) · Diabetes Care · doi:10.2337/dc09-0541 · Cited by 93 · cited 1×
“Young patients and older patients with a long duration of type 1 diabetes are at high risk for severe hypoglycemia due to impaired hypoglycemia awareness (2,5,6).”
BackgroundDanne, T., Tsioli, C., Kordonouri, O., Blaesig, S., Remus, K., Roy, A., Keenan, B., Lee, S. W., & Kaufman, F. R. (2014) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2013.0327 · Cited by 91 · cited 1×
“glycemia prevention with PLGS could involve a tradeoff of increased mean glucose and greater hyperglycemia in exchange for the protection of decreased hypoglycemia exposure (15,18).”
BackgroundO'Connell, S. M., Cooper, M. N., Bulsara, M. K., Davis, E. A., & Jones, T. W. (2011) · Diabetes Care · doi:10.2337/dc11-0748 · Cited by 81
Zhong, A., Choudhary, P., McMahon, C., Agrawal, P. K., Welsh, J. B., Cordero, T. L., & KAUFMAN, F. R. (2016) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0216 · Cited by 80 · cited 2×
“Relatively shorter suspensions were seen in the current study, with a mean suspension duration of 18 min per event, whereas suspensions for other trials were 56 and 58min (16,17).”
BackgroundBeck, R. W., Raghinaru, D., Wadwa, R. P., Chase, H. P., Maahs, D. M., Buckingham, B. A., & for the In Home Closed Loop Study Group (2014) · Diabetes Care · doi:10.2337/dc13-2775 · Cited by 45
Self-citationSpaic, T., Driscoll, M., Raghinaru, D., Buckingham, B. A., Wilson, D. M., Clinton, P., Chase, H. P., Maahs, D. M., Forlenza, G. P., Jost, E., et al. (2017) · Diabetes Care · doi:10.2337/dc16-1794 · Cited by 29
Self-citationForlenza, G. P., Raghinaru, D., Cameron, F. M., Bequette, B. W., Chase, H. P., Wadwa, R. P., Maahs, D. M., Jost, E., Ly, T. T., Wilson, D. M., et al. (2017) · Pediatric Diabetes · doi:10.1111/pedi.12603 · Cited by 28
Self-citationLy, T. T., Jones, T. W., Griffiths, A., Dart, J., Davis, E. A., Stick, S. M., & Wilson, A. C. (2011) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2011.0144 · Cited by 19 · cited 1×
“Young patients and older patients with a long duration of type 1 diabetes are at high risk for severe hypoglycemia due to impaired hypoglycemia awareness (2,5,6).”
Background
Cited by
Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes
Brown, S. A., Kovatchev, B. P., Raghinaru, D., Lum, J. W., Buckingham, B. A., Kudva, Y. C., Laffel, L. M., Levy, C. J., Pinsker, J. E., Wadwa, R. P., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1907863 · Cited by 1,030
Self-citation9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Bajaj, M., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s009 · Cited by 728
Self-citation9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Gaglia, J. L., Hilliard, M. E., Johnson, E. L., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s009 · Cited by 662
Self-citation15. Management of Diabetes in Pregnancy: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s015 · Cited by 504
A Randomized Trial of Closed-Loop Control in Children with Type 1 Diabetes
Breton, M. D., Kanapka, L. G., Beck, R. W., Ekhlaspour, L., Forlenza, G. P., Cengiz, E., Schoelwer, M., Ruedy, K. J., Jost, E., Carria, L., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2004736 · Cited by 455
Self-citation
Metadata
- Authors
- Forlenza, G. P., Li, Z., Buckingham, B. A., Pinsker, J. E., Cengiz, E., Wadwa, R. P., Ekhlaspour, L., Church, M. M., Weinzimer, S. A., Jost, E., Marcal, T., Andre, C., Carria, L., Swanson, V., Lum, J. W., Kollman, C., Woodall, W., & Beck, R. W.
- Affiliations
- University of Colorado Denver (US)
- Jaeb Center for Health Research (US)
- Stanford Medicine (US)
- Sansum Diabetes Research Institute (US)
- Yale University (US)
- Tandem Diabetes Care (United States) (US)
- Corresponding author
- Lum, John W.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2018-08-08
- Volume
- 41
- Issue
- 10
- Pages
- 2155-2161
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2886691517
- Cited by
- 246
- References
- 32
- Citations by year
- 2026: 9 · 2025: 16 · 2024: 30 · 2023: 32 · 2022: 28 · 2021: 50 · 2020: 38 · 2019: 41 · 2018: 2
- FWCI
- 26.08
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Keywords
- type 1 diabetes, hypoglycemia, predictive low glucose suspend, continuous glucose monitoring, insulin pump therapy, sensor-augmented pump, glycemic control, adolescents, children
- MeSH terms
- Adolescent, Adult, Aged, Algorithms, Blood Glucose, Child, Diabetes Mellitus, Type 1, Female, Humans, Hypoglycemia, Hypoglycemic Agents, Insulin, Insulin Infusion Systems, Male, Middle Aged, Blood Glucose Self-Monitoring, Drug Delivery Systems, Cross-Over Studies, Monitoring, Ambulatory, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.